Eudaven has pivoted from branded GLP-1s to a CareValidate-powered compounded program. This playbook re-fits positioning, customer-journey design, growth loops, and compliance to the regulatory reality of mid-2026 — and to a marketing operator who already speaks the language.
Category
Compounded GLP-1 telehealth
Clinical infra
CareValidate / CareGLP
Pharmacy network
503A: Belmar · Strive · Epiq · Casa
Regulatory posture
Patient-specific · Rx-individualized
Brand voice
Sage Vitality
Reading level
Operator · framework-fluent
Δ
The pivot, in three columns.
What changed
Supply moved from branded FDA-approved drugs (Wegovy, Zepbound) to 503A-compounded semaglutide and tirzepatide via CareGLP's pharmacy network. Insurance hybrid is largely off the table — most payers don't reimburse compounded.
What it means for the moat
The "we sell branded, they don't" story is gone. New defensibility levers: individualization rigor, care-experience quality, pharmacy-transparency, retention machinery, and compliance posture. Brand becomes the moat, not the molecule.
What it means for messaging
You operate inside a March 2026 FDA enforcement perimeter: no equivalence claims to branded drugs, no affordability-as-rationale, no off-label promotion. Lead instead with personalization, clinician oversight, and outcomes — without promising them.
01The Regulatory Clock · this is the gravity well
FDA enforcement timeline against compounded GLP-1s
● past ● now ○ pending
2022
Shortage declaredFDA places semaglutide & tirzepatide on shortage list — opens 503A/B compounding pathway.
Dec 2024 – Feb 2025
Shortages resolvedTirzepatide (Dec '24) then semaglutide (Feb '25) come off the list. Compounding rationale narrows.
Comment period closesFinal rule expected after. 503A patient-specific compounding survives — if individualization is real and documented.
02Where Eudaven sits · positioning map
Compounded GLP-1 competitive map
Y · brand quality of care · X · price & volume strategy
The slot
where to compete
The compounded category in 2026 is fragmented at the bottom (price wars, FDA letters, churn-and-burn) and thin at the top (premium care, defensible brand, high retention). That gap is the slot.
Eudaven's edge isn't the molecule — every competitor sources from the same handful of 503A pharmacies. Edge is built from clinician quality, onboarding rigor, retention design, and brand trust.
For health-engaged adults who want clinical care — not a checkout — Eudaven is the compounded GLP-1 program designed around individualized clinician oversight, transparent pharmacy sourcing, and outcomes that compound month over month.
03Customer journey · seven stages, JTBD framing
01
Awareness
top of funnel · brand discovery
Job-to-be-done"When I'm researching weight-loss medication options, I want to find providers I can trust enough to evaluate, so I can shortlist 2–3 without falling for the obvious red-flag operators."
Plays
Educational SEO ("what is compounded GLP-1")
Clinician-led short-form (TikTok / Reels)
Wellness & women's-health podcast sponsorships
Branded search defense (your name + competitors')
KPIs
ReachBranded SOVAided recallDirect sessions
Eudaven note: Meta's healthcare-vertical policy makes paid weight-loss creative high-friction. Plan for elevated CPMs (~30–60% above category average) and longer ad-account warmup. Compliant headlines lean on personalization and care quality, never price or brand-equivalence.
02
Consideration
mid-funnel · trust formation
Job-to-be-done"When I'm comparing 3 telehealth providers, I want clear answers on pharmacy quality, clinician credentials, and what 'compounded' actually means, so I can pick the one least likely to land me in a Reddit horror thread."
Eudaven note: "Trust scaffolding" is the differentiator. The category baseline is opaque pharmacy sourcing and stock-photo doctors. Naming Belmar / Strive / Epiq / Casa Pharma Rx with their 503A status, USP-797 standards, and third-party testing flips a known weakness into a category advantage.
03
Acquisition
bottom of funnel · conversion
Job-to-be-done"When I've decided to try this, I want a clinical intake that feels like care — not a checkout — so I trust the prescription that comes out the other side."
Plays
Quiz → consult booking (charge after approval)
Real-clinician video at intake completion
State availability + ineligibility transparency
FSA/HSA payment positioning (compliant framing)
KPIs
CACCAC paybackQuiz→Rx %MER
Eudaven note: The "charge only after clinical approval" pattern is now also a regulatory asset, not just a UX one — it documents that compounding is preceded by clinician evaluation rather than triggered by the purchase. Make this visible on the pricing page in plain English.
04
Activation
first value · onboarding
Job-to-be-done"When my first vial arrives, I want to feel like a clinic, not Amazon — clear instructions, a real person to ask, and a sense of where this is going for me specifically."
Plays
Welcome series (5–7 emails + 2 SMS)
Care-team intro video (real, named clinician)
Day-2 SMS symptom check, Day-7 expectation reset
"Activation moment" engineered: first injection logged + first weight check-in by Day 14
KPIs
TT-First RxOnboard %D7 activeD14 activation
Eudaven note: Activation is also an adverse-event-detection surface. Day-2 SMS isn't just retention — it's the catch-net for early dosing or tolerability issues, which the FDA has been pointing to in compounded enforcement. Treat clinical and marketing instrumentation as one system.
05
Retention
recurring revenue · the real game
Job-to-be-done"When I'm 60+ days in and questioning the spend, I want enough proof of progress and warmth from the care team to keep going through the awkward middle."
Cohort-stratified content (M2 vs M4 patient ≠ same)
KPIs
M3 retentionLogo churnNPSCohort LTV curves
Eudaven note: Compounded compresses the LTV ceiling vs branded (lower price), so the only path to LTV:CAC ≥ 3 is retention months. Every month past M3 is gross-margin gold. Engineer for M6 like a SaaS company engineers for net retention.
06
Expansion
ARPU growth · cross-sell
Job-to-be-done"When the GLP-1 piece is working, I want my care team to keep guiding me on the next thing — sleep, hormones, longevity — instead of me re-searching from scratch."
Eudaven note: CareValidate's full menu (GLP-1, peptides, HRT/TRT, skincare) is your strategic pantry. Don't launch all five — sequence them. Earn GLP-1 trust first, then HRT/skincare in months 6–12 once retention curves are stable.
07
Advocacy · your cheapest CAC line item, by far
word of mouth · referrals · UGC
Job-to-be-done"When my friend asks 'what are you doing differently?', I want a clean way to refer them — that doesn't feel like I'm pitching, and rewards both of us for the recommendation."
Plays
$50 give / $50 get credit program
NPS-9-or-10 trigger → referral ask
Patient-story library (with written consent)
Compliance-safe UGC: process & experience, not before/after
Referred patients typically cost ~70% less to acquire and retain longer. In a category with elevated CPMs and tight ad-account scrutiny, building the referral loop is closer to infrastructure than to a marketing tactic.
Eudaven note: Compounded UGC carries unique risk — before/after photos with weight numbers can read as outcome promises. Frame patient stories around experience: "what week 4 felt like," "how my care team helped." Get written consent that survives FTC scrutiny.
04Growth loops · compounding beats funneling
A funnel converts a fixed cohort once. A loop turns each output back into the input, so growth compounds. Healthcare is hostile to ad-driven funnels (high CPMs, regulatory scrutiny) and friendly to loops (high-trust referrals). Build for loops first.
Word-of-Mouth Loop
Highest leverage · slowest start
Patients who hit M3 with strong outcomes refer a friend → friend converts at 2–3× the cold rate → friend's outcomes feed back into NPS & UGC pool.
Patient activates & retains past M3
NPS ≥ 9 triggers referral ask
Referral credit + clean share asset
Friend signs up at premium CR
Multiplier: K-factor target ≥ 0.4 by M9
Content / SEO Loop
Compounds for years
Long-form clinical content earns search rank → ranked content captures high-intent traffic → conversions fund more content → deeper topic authority earns more rank.
Publish clinician-reviewed long-form
Rank for "compounded GLP-1" mid-tail
Internal linking + PR backlinks
Traffic → quiz → patient → reinvest
Multiplier: 8–14× ROI by month 18 vs paid-only
Paid Acquisition Loop
Fastest signal · weakest moat
Paid drives patients → patient data improves model targeting → server-side conversion signal sharpens lookalikes → blended CAC drops → reinvest savings into channel expansion.
Run paid with proper CAPI / hashed events
Cohort-tag patients in attribution layer
Feed M3-retention signal back to platform
Optimize for retained patients, not signups
Multiplier: Bid on retention, not conversion. CAC drops 20–40% over 90 days.
05Guardrails & Unit Economics
Compounded-era compliance
post-March 2026 enforcement reality
FDA bright line · March 202630 telehealth warning letters cited "same as / equivalent to" branded-drug language. Entire campaigns can be killed by one phrase. Treat copy review as a release gate, not a step.
✕
No equivalence claims. Never "same as Wegovy / Ozempic / Mounjaro / Zepbound." Never "generic" — there are no FDA-approved generics for these. Compounded ≠ generic.
✕
No affordability-as-rationale. FDA explicitly rejects price/insurance access as "clinical need" for compounding. Position around personalization, not price.
✕
No off-label promotion. Microdosing for cosmetic / sub-clinical-BMI use is FDA off-label promotion. Hard line.
✕
No outcome guarantees. "Lose X lbs" = FTC violation. Always include "results vary," and never tie results to compounded preparations.
✕
No PHI in ad pixels. Meta Pixel + PHI is the most-litigated healthcare-marketing pattern of 2023–2025. Server-side, hashed, scrubbed.
✓
Document individualization. Each Rx must reflect patient-specific clinical evaluation. Build the audit trail into the EMR — it's also a marketing asset (transparency page).
✓
Disclose pharmacy partners. Name your 503A pharmacies, USP-797 standard, third-party COA testing. Industry-leading transparency = differentiation in a category that hides this.
✓
Three-layer safety disclosure on every conversion surface: side effects, contraindications, who shouldn't take it.
M3 retention% active at day 90 · the gating metric
≥ 65%
LTV (6-mo cohort floor)ARPU × margin × avg months
~$780
LTV : CAChealthy ≥ 3
≥ 3.1×
The single biggest lever in this model is not CAC — it's M3 retention. Moving from 50%→65% lifts LTV ~30% without touching ad spend. Build for retention before you build for scale.
30 / 60 / 90 day plan
working backward from a defensible LTV:CAC
30DAYS
Foundations & compliance posture
Goal · launch with the compliance perimeter set, not retrofitted.
Regulatory watch: FDA final rule decision (post Jun 29 comment close)
06Channel mix · healthcare-vertical realities
Paid · rented
Meta & Google Ads
$3K–$30K/mo to learn
Healthcare-vertical creative passes through extra review. Compliant copy is harder, CPMs run higher. Use server-side conversions and never optimize on signup events alone.
⚠ ELEVATED COMPLIANCE LOAD
Organic · earned over time
SEO & Short-form video
3–9 month payoff
Compounds. One credentialed clinician on camera beats 6-figure ad spend in this category. Topic authority on "compounded done responsibly" is a wide-open lane.
Owned · controlled
Email · SMS · App
Highest ROI of any channel
Where retention & revenue are won. For a compressed-LTV compounded model, lifecycle automation is the single highest-leverage marketing investment.
Earned · others vouch
PR · Reviews · Referrals
Trust multiplier
Pitch responsible-compounding angles to wellness/business press. Trustpilot & Google reviews triggered post-D45. In a regulated, trust-driven market, earned outperforms paid 3:1 on intent.
CAC payback
CAC ÷ contribution margin/mo
Months to recoup CAC. Aim < 2 mo for compounded models.
LTV : CAC
LTV ÷ CAC
Below 3 = leaky bucket. Fix retention before scaling.
M3 retention
% of cohort active at day 90
The single best predictor of business viability.
MER
total revenue ÷ total ad spend
Blended efficiency. Use alongside CAC, not instead.